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INNATE IMMUNE RESPONSES OF VAGINAL EPITHELIUM AND ACTIVITY 
OF MONOCLONAL ANTIBODY-BASED MICROBICIDE IN THE PRESENCE 
OF LACTIC ACID, A LACTOBACILLUS METABOLITE 
 
LOIS BAYIGGA 
ABSTRACT  
Sexually transmitted infections (STIs) such as gonorrhea, herpes simplex virus 2 (HSV 
2), hepatitis C, human papilloma viruses (HPV) and human immunodeficiency virus type 
1 (HIV) are a global health concern affecting millions of lives. Although extensive efforts 
have been geared towards prevention and treatment of STIs, little progress has been 
achieved. Recently, efforts to develop microbicides have been focused on the commensal 
bacterial species that comprise the vaginal microbiome and their role in immunity and 
disease pathogenesis. The lower FRT which includes the cervix and vagina has 
endogenous bacterial species that are supported by the mucosal epithelium. Lactobaccilli 
are the dominant endogenous bacterial species in the vagina of most women; lactobacilli 
convert glycogen to lactic acid (LA) which maintains a low pH environment in the vagina 
and serves as a deterrent to infectious organisms.  The purpose of this research project 
was to determine the effects of LA on vaginal integrity and inflammation in a vaginal 
epithelial cell (VEC) tissue model, and on the ability of the broadly neutralizing anti-HIV 
antibody, VRCO1, to inactivate HIV in vitro.  
Effects of LA exposure on the viability and integrity of vaginal epithelium were 
determined by histology, MTT assay and measurement of transepithelial electric 
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resistance (TEER). In addition, an enzyme-linked immunosorbent assay (ELISA) was 
used to measure concentrations of cytokines secreted by the VEC epithelial cells in 
response to different doses of LA. Using TLR agonists to simulate infection in the VEC 
model, we tested the hypothesis that LA has anti-inflammatory properties that modulate 
immune responses of the vaginal epithelium. We assessed the effect of LA on the 
neutralization activity of the anti-HIV-1 monoclonal antibody VRCO1 in the TZM-bl 
HIV neutralization assay.  
Tissue morphology and integrity were not affected by exposure to LA. Low 
concentrations of IL-1β and RANTES were expressed by VEC tissues in response to L-
LA treatment. VEC tissues expressed significantly elevated concentrations of IL-1RA 
(p<0.0001), an anti-inflammatory cytokine, in response to LA regardless of incubation 
time and LA doses. In addition, treatment of VEC tissues with Poly I: C in the presence 
of  LA dampened upregulated expression of IL-1β, TNF-alpha and IL-6 in response to 
the TLR 3 agonist. LA also elicited significantly higher IL-1RA concentrations when 
apically added to the TLR agonist-treated VEC tissues. These data suggest that LA elicits 
an anti-inflammatory response in the vaginal epithelium. LA acidic conditions as low as 
pH 3.5 did not affect the ability of VRC01, to prevent HIV infection. We found that LA, 
at concentrations present in vaginal secretions of normal women, inhibited the 
inflammatory response to a TLR agonist, possibly due to upregulated Il-1RA synthesis. 
In addition, the functionality of VRCO1 in an acidic milieu was not diminished, 
providing evidence that antibodies can function in the low pH vaginal environment. This 
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report highlights the potential use of LA in the vagina as a microbicide due to its 
virucidal activity and anti-inflammatory properties. It also indicates that monoclonal 
antibody-based vaginal microbicides will not be neutralized by LA. There is still a need 
to elucidate the exact mechanisms by which LA confers immuno-modulatory properties 
within the female reproductive tract. 
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INTRODUCTION 
1.1   BURDEN OF SEXUALLY TRANSMITTED DISEASES 
Sexually transmitted infections  (STIs) caused by pathogens such as Neisseria gonorrhea, 
herpes simplex virus 2 (HSV 2), hepatitis C virus, human papilloma viruses (HPV) , 
Chlamydia trachomatis  and human immunodeficiency virus (HIV) are a global health 
concern affecting millions of lives. STIs affect both the reproductive fecundity of 
individuals and their quality of life. An estimated 35 million people were living with 
HIV/AIDS in 2014 with 70% of disease burden in sub-Saharan Africa (UNAIDS 2014). 
The World Health Organization (WHO) in 2015 reported an estimated 500 million people 
were living with genital HSV and 290 million women having HPV infection (WHO). The 
overwhelming burden of STIs is further emphasized by the number of new gonorrhea (78 
million) and trichomoniasis cases (143 million) (WHO) reported each year. In the United 
States, approximately 1.5 million cases of Chlamydia trachomatis infection were reported 
to the CDC in 2014 and females were twice as likely to be infected compared to males 
(Prevention 2015). Given that certain STIs such as syphilis and HIV can be transmitted 
congenitally, this poses a particular challenge in disease prevention strategies. Sexually 
transmitted infections in females are associated with a significant number of obstetric and 
gynecological complications such as pre-term births, still births, ectopic pregnancy, 
cervical cancer, and pelvic inflammatory disease which can lead to tubal scarring and 
subsequent infertility.  
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Although extensive efforts have been geared towards prevention and treatment of STIs, 
little progress has been achieved. Current strategies to mitigate the burden of these 
infections include promotion of condom use and sexual behavioral changes, male 
circumcision (Gray, Kigozi et al. 2007), public health education and treatment with 
antibiotics and antiretroviral therapy (ART). A vaccine was recently introduced for the 
prevention of HPV infections (Garland, Cheung et al. 2015). The emergence of drug 
resistant strains of pathogens that cause STDs, for example Neisseria gonorrhea and 
Treponema pallidum have greatly hampered efforts in eradicating these diseases, 
emphasizing the need for development of more effective antibiotics or vaccines. ART has 
greatly improved the health and quality of life of people living with HIV/AIDS. In 
addition, it is greatly effective at reducing HIV transmission from mother-to-child and 
between sexual partners (Teasdale, Marais et al. 2011). However, access to ART in sub-
Saharan Africa, which has the highest disease burden, is still very limited due to expense 
and inadequate availability of routine health care thus hindering progress in the fight 
against HIV. Efforts to develop topical microbicides against HIV have yielded poor 
results during clinical trials and have been greatly affected by poor compliance among 
the study participants (Buchbinder, Mehrotra et al. 2008; Rerks-Ngarm, Pitisuttithum et 
al. 2009; Abdool Karim, Richardson et al. 2011). Development of vaccines against STDs 
has not been successful, except for the HPV vaccine, which calls for further exploration 
of the immune system and its role in combating STDs and other genital infections. 
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1.2 IMMUNE DEFENSE OF THE FEMALE REPRODUCTIVE SYSTEM 
The female reproductive tract (FRT) has several immune defenses including the physical 
barrier provided by the stratified vaginal epithelium, cervico-vaginal mucus, innate 
immunity mediated by anti-microbial peptides and other factors, commensal bacteria and 
adaptive immune functions of lymphocytes and antigen presenting cells that reside in the 
mucosal layer of the vagina and cervix (Wira, Fahey et al. 2005; Hickey, Patel et al. 
2011; Anderson, Marathe et al. 2014). The mucosal epithelium acts as a mechanical 
barrier to invading pathogens and supports commensal bacterial species that comprise the 
vaginal microbiome. Vaginal microbiota provide protection against invading microbes by 
competitive exclusion of genitourinary pathogens from receptors present on the surface 
of the genitourinary epithelium. In addition, organisms such as the Lactobacillus species 
maintain the acidic pH of the vagina by producing lactic acid via glycogen cleavage in 
epithelial cells (Boskey, Cone et al. 2001; Wilson, Roach et al. 2010) Cervicovaginal 
mucus traps exogenous organisms and also contains antimicrobial agents such as 
defensins (King, Fleming et al. 2003)  and antibodies (Belec, Ghys et al. 2001; Donadoni, 
Bisighini et al. 2010).  
Innate immune responses at the mucosal surfaces of the FRT rely on the recognition of 
highly conserved pathogen-associated molecular patterns (PAMPs) by pattern recognition 
receptors (PRRs). PAMPs are characteristically invariant, essential for a pathogen’s 
survival and distinguishable from the host. Examples of PAMPs  include 
lipopolysaccharide (LPS) produced by gram negative bacteria, double stranded RNA 
found in replicating viruses and unmethylated CpG DNA sequences found in bacteria. 
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PRRs are widely expressed by many cell types within the FRT including endothelial 
cells, fibroblasts and epithelial cells, although expression varies across the organs in the 
FRT (Mogensen 2009). Major PRRs include Toll-like receptors (TLRs), NOD-like 
receptors (NLRs), c-type lectin receptors and RIG-I like receptors (RLRs). TLRs are the 
most extensively studied  PRRs in humans and are broadly classified into two groups: 
TLRs 1, 2,4, 5 and 6, which are expressed on the cell plasma membrane and recognize 
lipid PAMPs, and TLRs 3, 7, 8 and 9, which are found in endosomes and detect microbial 
nucleic acids (Akira, Uematsu et al. 2006). Engagement of PRRs with their respective 
PAMPs leads to signal transduction and subsequent expression of genes that are involved 
in innate immune responses (Nasu and Narahara 2010; Joseph, Zalenskaya et al. 2012; 
Sathe and Reddy 2014). 
Antigen presenting cells such as Langerhans cells and macrophages play a pivotal role in 
linking innate immune responses to the adaptive immune system. Within the FRT, 
immune cells such as T cells, natural killer cells (NK cells), macrophages and B cells are 
differentially distributed in each organ of the FRT (Pudney, Quayle et al. 2005). The 
lamina propria of the cervix and vagina has numerous CD3+ T cells of which cytotoxic 
CD8+ T cells are the most dominant (Lee, Kim et al. 2015). B cells are rarely found 
within the FRT and only localize within T cell aggregates that are in the cervix. In 
contrast to B cells, immunoglobulin producing CD38+ plasma cells are found scattered 
within the lamina propria of the cervix and do not closely localize with T cells 
(Johansson, Rudin et al. 1999). The T and B cells confer protection against invading 
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pathogens by producing cytokines and antibody responses respectively.  Cytotoxic  T 
cells, NK cells and macrophages also participate in cell-mediated cytotoxicity functions 
Within the lower FRT including the cervix and vagina, low levels of immunoglobulin 
(Ig) A and IgG are maintained and the uterine cavity has IgG whose levels peak during 
the peri-ovulatory period (Lee, Kim et al. 2015). Antimicrobial peptides produced by the 
mucosa of the FRT include lactoferrin, secretory leukocyte peptidase inhibitor (SLPI), β-
defensin 1-2 (HBD 1-2), and elafin. High estrogen concentration significantly affects the 
secretion of these antimicrobial molecules and pro-inflammatory cytokines within the 
FRT (Wira, Fahey et al. 2014). 
1.3 VAGINAL MICROBIOME 
Recently, efforts have been focused on the commensal bacterial species that comprise the 
vaginal microbiome and their role in immunity and disease pathogenesis. The lower FRT, 
which includes the cervix and vagina, has endogenous bacterial species that are supported 
by the mucosal epithelium. In healthy, asymptomatic women, there are five distinct 
microbial communities, the majority of which are dominated by Lactobacillus species. 
Community types I, II, III and V are predominantly Lactobacillus crispatus, 
Lactobacillus gasseri, Lactobacillus iners and Lactobacillus jensenii   respectively, while 
a greater diversity of taxa are found in community type IV, with a predominance of strict 
anaerobes (Ravel, Gajer et al. 2011).  A shift in the composition of the vaginal 
microbiome i.e. loss of lactobacilli and/or overgrowth of other bacterial species, mostly 
anaerobic bacteria such as Gardnerella species leads to bacterial vaginosis. Bacterial 
vaginosis is a common sexually-associated condition among women related to pregnancy 
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and gynecological complications, pelvic inflammatory disease, increased sexually 
transmitted infections (STI) and HIV acquisition (Donders 2010; Donders, Bellen et al. 
2011). In contrast, a Lactobacillus-dominated vaginal microbiome has been associated 
with better reproductive health outcomes, thus highlighting its role in protection against 
sexually transmitted infections. According to Amsel’s criteria, bacterial vaginosis (BV) is 
diagnosed clinically as having three of the following criteria:  alkaline vaginal pH (pH 
greater than 4.5), presence of clue cells in cervicovaginal fluid, a milky homogenous 
vaginal discharge and release of a fishy odour upon addition of 10% potassium hydroxide 
to cervicovaginal fluid (Amsel, Totten et al. 1983). The composition of the vaginal 
microbiome is influenced by the cyclic menstrual cycle, ethnicity, age, sexual activity 
and hygiene practices (Ness, Hillier et al. 2002; Ravel, Gajer et al. 2011; Gajer, Brotman 
et al. 2012; Ravel, Gajer et al. 2012). Whereas a majority of women in western countries 
have “healthy” lactobacillus dominant vaginal microflora, dysbiotic vaginal microflora 
predominated in a majority of women in many developing countries with a high 
prevalence of STIs including HIV (Ravel, Gajer et al. 2011; Borgdorff, Tsivtsivadze et al. 
2014; Gautam, Borgdorff et al. 2015). 
Lactobacilli acidify the vaginal ecosystem through production of lactic acid (LA) as a 
result of anaerobic metabolism of glycogen which is found within vaginal epithelial cells. 
D-LA is exclusively a bacterial product yet L-LA can also be produced by vaginal 
epithelial cells especially during periods of high estrogen levels.  Bacteria contribute a 
higher percentage to the lactic acid pool found in the vaginal micro-environment as 
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evidenced by the high D to L-LA  ratio (Boskey, Cone et al. 2001). The low pH of the 
vaginal environment is restrictive to the growth and survival of invading microbes. 
Bacterial vaginosis (BV)-associated bacteria produce short chain fatty acids (Aroutcheva, 
Gariti et al. 2001; Yeoman, Thomas et al. 2013) that contribute to the dysbiotic 
environment that increases risk of sexually transmitted diseases (STDs) (Cherpes, Meyn 
et al. 2003; Allsworth and Peipert 2007; Cohen, Lingappa et al. 2012). LA inactivates 
HIV-1 and may potentially have anti-inflammatory effects in the vaginal epithelium, thus 
lowering the overall risk of HIV transmission. Yamamoto, Xu et al. (2013) explored the 
homeostatic properties of Lactobacillus jensenii engineered as a live anti-HIV 
microbicide and found out that colonization of cervicovaginal cells with both wild-type 
and engineered L.jensenii did not elicit an inflammatory response despite inducing NF-
kB gene expression (Yamamoto, Xu et al. 2013). Studies on the immunomodulatory role 
of LA in the gastrointestinal tract indicate that LA has anti-inflammatory effects in the 
epithelium, and also modulates the function of immune cells (Menard, Candalh et al. 
2004) but this cannot simply be extrapolated to the unique environment of the FRT 
without extensive studies.  Apart from acidifying the vaginal micro-environment through 
lactic acid production, the exact mechanisms by which Lactobacillus species and its 
metabolite, LA, promote vaginal health is poorly understood. A better understanding and 
characterization of the modulatory effects of LA on the immune defenses in the female 
reproductive tract would provide a foundation for better insight into the defense of the 
human vagina, and in potentially developing a microbicide with similar protective 
properties. 
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1.4 CURRENT STUDY 
In this study, we used an organotypic human vaginal epithelial cell (VEC) tissue model to 
assess the effect of LA on both innate immune responses and inflammation within the 
FRT. The VEC tissue model has similar morphological and structural properties as the 
stratified, non-keratinizing epithelium of the vagina thus it was suitable for use in these 
studies. Effects of LA exposure on the viability and integrity of vaginal epithelium were 
measured using the MTT assay and transepithelial electric resistance (TEER). In 
addition, an enzyme-linked immunosorbent assay (ELISA) was used to measure 
concentrations of cytokines secreted by the epithelial cells in response to different doses 
of LA. Using TLR agonists to simulate inflammation in the VEC model, we tested the 
hypothesis that LA had anti-inflammatory properties that modulated immune responses 
of the vaginal epithelium. We also assessed the effect of LA on the neutralization activity 
of anti-HIV-1 monoclonal antibodies. These antibodies were developed as a potential 
microbicide therefore it was critical to assess their activity under conditions that are 
similar to those found in vivo where they would be applied. Overall, the main objective of 
the study was to assess the effect of LA, a metabolite of vaginal bacteria, on immune 
responses and inflammation of the vaginal epithelium. 
1.5 HYPOTHESIS 
Lactic acid, a metabolite of Lactobacillus species, suppresses inflammation in the vagina, 
but has no effect on antibody-mediated humoral immunity.   
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 VRCO1-N ANTI-HIV MONOCLONAL ANTIBODIES  
VRCO1 is a monoclonal antibody that targets the CD4-binding site on gp120, an surface 
HIV-1 envelope protein, and it neutralizes approximately 90% of diverse HIV-1 primary 
isolates; hence it is referred to as a broadly neutralizing antibody (Wu, Yang et al. 2010). 
Given its anti-HIV-1 activity, VRCO1 has been incorporated into a film, MB66, to be 
used as a topical vaginal microbicide, and its potential is currently being evaluated in 
clinical trials. The VRCO1 antibody currently being used in the MB66 microbicide was 
produced by Mapp Biopharmaceuticals by transgenic engineering in Nicotiana plants and 
is thus called a plantibody. The microbicide film, MB66 is composed of polyvinyl 
alcohol (60%), maltitol (25%), histidine (0.1%), polysorbate 20 (0.01%), water (5%), 
HSV8-N monoclonal plantibody (5%), and VRCO1-N monoclonal plantibody (5%).  The 
MB66 film contains 10 mg of VRCO1-N and 10 mg of HSV8-N. This film is 2 inches by 
2 inches, with a thickness of 0.06 mm and a mass of 0.2 grams. The placebo film includes 
all of the same components as the active film, except for the HSV8-N and VRCO1-N 
monoclonal plantibodies. 
Previously, neutralization activity of VRCO1 in film or solution form has been tested in-
vitro at neutral pH (pH 7.4). However, this film is to be utilized in the acidic vaginal 
environment and therefore, it is pertinent to test it at the same physiological conditions 
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that closely relate to the in-vivo conditions where it will be applied. In this study, we 
evaluated the neutralization activity of the VRCO1 antibody at acidic pH. 
2.2 TZM-BL ASSAY (NEUTRALIZATION ASSAY) 
Using a modified Montefiori Neutralization assay, the effect of lactic acid on the anti-
HIV activity of VRCO1-N and MB66 film was assessed. Briefly, the MB66 and placebo 
films were cut into quarters and a quarter of each film was immersed in 1mL of TZM-BL 
media (DMEM containing 10% FBS, 1% PBS, 1% 2Mm L-glutamine). Estimated 
concentration of VRCO1 plantibody in solution was 1 mg/ml. Solubilized MB66 film, 
placebo film and VRCO1 were each incubated in 270ul of 1% L-lactic acid (30% L-
Lactic acid stock diluted in TZM-BL media and pH adjusted with 1M sodium hydroxide), 
at pH 3.0-3.5 at 37°C for 2, 4 and 24 hours. These conditions represent the normal human 
vaginal environment (Boskey, Cone et al. 2001; O'Hanlon, Moench et al. 2013). 
Solubilized MB66 film and VRCO1, each incubated in normal media were used as 
positive controls, and placebo film solubilized in media only was used as a negative 
control. 
Subsequent to incubation with 1% L-lactic acid, the acid-treated plantibodies and 
placebo-film were neutralized with 20uL of 100Mm HEPES buffer and 25uL of 1M 
sodium hydroxide. In a 96-well plate, both neutralized plantibody and placebo solutions 
were serially diluted (four ten-fold dilutions) in TZM-BL media. Fifty micro-liters (50uL) 
BAL or Q23-17 HIV-1 virus (20 IP/uL) were incubated with the various concentrations 
of acid-treated plantibodies for 2, 4 and 24 hours at 37°C.  Following incubation, 100uL 
 11 
 
of TZM-BL cells (1X 10
4 
cells per well) and DEAE-dextran (1:1000) were added to each 
well and cultures were incubated at 37°C for 48 hours. HIV infection of TZM-BL cells 
was measured using chemiluminescent β-galactosidase reporter assay. 
Briefly, cultured cells were washed twice with PBS and then lysed with 20uL of lysis 
buffer per well for 15 minutes at 37°C. To each well, 70uL of diluted, pre-warmed beta-
galactosidase (1:100) was added and the plate was incubated on a shaker for 1 hour at 
room temperature. Following incubation, accelerator (100uL) was added to each well and 
the luminescence of beta-galactosidase activity was measured by a micro-plate reader. 
2.3 MatTEK VEC-100 FT™ TISSUE MODEL  
A human organotypic vaginal epithelial cell (VEC) tissue model produced by the MatTek 
Corporation, Ashland, MA, USA, was used in this study. The EpiVaginal™ VEC-100-FT 
tissue (VEC model), a three-dimensional tissue model reconstructed using primary  
vaginal ecto-cervical epithelial cells and fibroblasts, is well stratified, containing 
differentiated basal, supra-basal, intermediate, and superficial cell layers similar to in vivo 
tissue (Ayehunie, Cannon et al. 2006). 
Most studies on effects of Lactobacilli colonization on immune responses within the FRT 
have used monolayer cultures vaginal epithelial cell lines such as VK2/E6E7, which are 
immortalized cell lines, or primary cell lines. Although immortalized cell lines are quite 
inexpensive, have the same morphological features as primary cells and may possess 
some immunological and biochemical markers similar to the primary cells, they do not 
necessarily behave like primary cells due to the genetic manipulation (Kaur and Dufour 
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2012). Another major complication of using cell lines is contamination with other cell 
lines and/or mycoplasma (Nikfarjam and Farzaneh 2012). Use of primary cells avoid 
many of these problems, but primary epithelial cells are usually grown as monolayers and 
do not represent the fully differentiated vaginal epithelium.  In addition, use of cell lines 
or primary cells involves use of media and other growth factors but this does not take into 
account the other in-vivo interactions between cells of different systems that occur within 
their natural environment and may be vital to the hypothesis being tested. 
 
The organotypic VEC tissue model has many advantages over other in-vitro models in 
that: 1) it can be cultured for relatively longer time period (e.g. 2–3 weeks), 2) a large 
number of tissues can be produced from a single donor, therefore tissue-to-tissue 
variability is reduced, 3) there are fewer regulatory constraints, and 4) the tissue can be 
 
Figure 1.  VEC tissue 
H&E stained histological cross-sections of: (A) in vitro reconstructed VEC epithelial 
tissue model containing differentiated epithelial cells, (B) human vaginal tissue 
explants 
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reconstructed in the presence/absence of endocrine hormones or different cell types to 
mimic its in-vivo counterpart. It is relatively much cheaper than the animal models used 
to study sexually transmitted infections and is morphologically very similar to native in-
vivo tissue. Use of the VEC model also eliminates the challenges of anatomical 
differences, species variations and limited responsiveness to human pathogens which 
arise when using animal models. This tissue model has previously been used to study 
vaginal irritation (Ayehunie, Cannon et al. 2011) and the safety of vaginal microbicides 
(Mahalingam, Simmons et al. 2011).  
 
2.4 TREATMENT OF VEC TISSUES WITH L-LACTIC ACID 
VEC tissues were equilibrated at 37°C overnight in 500uL of VEC-100 FT maintenance 
media applied to the basal chamber. The following day, the tissues were transferred to a 
new culture plate with 500uL of maintenance media per well. Tissue integrity was 
assessed by measuring transepithelial electric resistance (TEER) of each tissue.  L-lactic 
acid (50uL) at 0.5%, 1%, 2% and 4%, pH 3.9 was added to the apical chambers of the 
tissues. Media was used as a negative control and TNF-α (10ug/mL) was used as a 
positive control.  Treatments were run in quadruplicates. Tissues were incubated for three 
hours at 37°C, 5% carbon dioxide (CO2). 
Table 1: Preparation of L-lactic acid solutions 
Concentration (%w/w) 0.5% 1.0% 2% 4% 
Media (uL) 983.3 966.7 933.3 866.6 
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30% (w/w) L-Lactic acid 
(uL) 
16.7 33.3 66.7 133.3 
1M sodium hydroxide (uL) 15 45 113 150 
pH 3.9 3.9 3.9 3.9 
 
 At the half-way mark of incubation, 50uL of either media or L-lactic acid at different 
concentrations were added to the apical chambers of the respective tissues. The apical 
chambers of the tissues were washed once with 500uL of media after 3 hour incubation. 
The tissues were then transferred to a new culture plate containing 500uL of fresh media 
per well and incubated for a further 18 hours at 37°C, 5% carbon dioxide (CO2).  
Following incubation, 500uL was added to apical chamber of each well and both the 
apical and basal supernatants were collected and stored at -80°C pending cytokine 
analysis. The TEER of each tissue was re-assessed after incubation. The pH of media and 
L-lactic acid was measured at 0, 1.5, 3 and at 21 hours post-incubation. Tissue viability 
was assessed by MTT assay and histology. 
2.5 TREATMENT OF VEC TISSUES WITH TLR AGONISTS (INFECTION  
MODEL) 
VEC tissues were equilibrated at 37°C overnight in 500uL of VEC-100 FT maintenance 
media applied to the basal chamber. The following day, the tissues were transferred to a 
new culture plate with 500uL of maintenance media per well. Tissue integrity was 
assessed by measuring transepithelial electric resistance (TEER) of each tissue.  Tissues 
were stimulated for 24 hours at either the apical or the basolateral surface with Poly (I: 
C), a TLR 3 agonist and Pam3CSK4, a TLR 1/2 agonist in the presence or absence of 1% 
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(w/w) L-lactic acid (pH 3.9) at the apical surface. TLR agonists used in this study were 
obtained from ThermoScientific and are described in table 2. Tumor necrosis factor alpha 
(TNF-α) was used as a positive inflammation control and media was used as a negative 
control. For cytokines and chemokines assessment, 500uL of supernatant were collected 
from the apical surface and the medium in contact with the basolateral surface of the 
tissues as described previously. 
Tissue integrity and viability was assessed by measurement of TEER and MTT assay 
respectively. Tissue morphology after treatment was also determined by histological 
staining. 
Table 2: TLR agonists 
Name Specificity  Concentration used pH 
Pam3CSK4 TLR 1/2 100ng/mL Unadjusted pH 
Poly (I: C) TLR 3 25ug/mL Unadjusted pH 
TNF-alpha Positive control 10ug/mL Unadjusted pH 
 
2.6 MTT CELL PROLIFERATION ASSAY 
The MTT assay was performed after treating the VEC tissues with L-lactic acid or TLR 
agonists and this was to assess tissue viability. The MTT assay involves the conversion of 
the water soluble MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) 
to an insoluble formazan. ATCC
® 
MTT cell proliferation assay involved addition of 10uL 
of MTT reagent to each tissues including controls followed by a two hour incubation 
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period at 37°C. Tissues were viewed periodically for presence of a purple precipitate 
which is an insoluble formazan. When purple precipitate was clearly visible, 100uL of 
detergent reagent was added to the tissues. To ensure full exposure of cells to detergent, 
tissues were gently broken down and mixed with detergent. Tissues were incubated 
overnight at room temperature. The following day, absorbance of each well was 
measured at 570nm in a microtiter plate reader. 
2.7 MAGPIX MULTIPLEX IMMUNOASSAY  
The concentrations of cytokines and chemokines secreted by VEC tissues in response to 
treatment with L-lactic acid and TLR agonists were measured using ProcartaPlex™ 
multiplex immunoassay. Briefly, 50uL of tissue culture supernatants and standards were 
added to 50uL of washed antibody magnetic beads in each well of a 96 well plate. This 
was followed by two hour incubation with shaking in the dark at room temperature. The 
plate was washed twice and 25uL of detection antibody was added to each well. The plate 
was sealed and incubated on a shaker for 30 minutes at room temperature in the dark. The 
plate was washed twice and 50uL of streptavidin-PE was added to each well. The plate 
was sealed and incubated on a shaker for 30 minutes at room temperature in the dark 
followed by washing. Reading buffer (120uL) was added to each well and the plate was 
shaken for five minutes at room temperature. Absorbance was measured by a Luminex 
instrument and concentration of cytokines or chemokines was determined from a 
standard curve. In this study, we measured concentrations of IL-1 beta, IL-1RA, TNF-
alpha, IL-6, RANTES and IL-8. 
 17 
 
2.8 HISTOLOGY 
Tissues were fixed with 10% methanol-free buffered formaldehyde, processed through 
graded ethanols and embedded in paraffin wax. Five-micrometer-thick sections of tissue 
samples were collected on glass slides, de-waxed, and rehydrated in a graded series of 
ethanols. Sections were then stained with hematoxylin and eosin stains and observed 
under a microscope. 
2.9 STATISTICAL ANALYSIS 
Data from neutralization assays were entered into Microsoft Excel spreadsheets and the 
percentage inhibition and SEM were calculated. For comparisons between different 
treatment groups, data from Excel spreadsheets was analyzed and plotted using GraphPad 
Prism software.  Values reported were means+ SEM and comparisons were made using 
the Holm-Sidak method. Data from treatment with L-LA and TLR agonists was analyzed 
using two-way ANOVA and multiple comparisons were made using Dunnett’s or 
Tukey’s multiple comparisons tests. A significance level of 0.05 was set for all statistical 
tests. 
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CHAPTER THREE 
RESULTS 
3.1 ACTIVITY OF VRCO1 IN ACIDIC ENVIRONMENT 
VRCO1, a broadly neutralizing anti-HIV-1 monoclonal antibody has been developed into 
a microbicide film and its activity has been assessed in an environment at neutral pH (pH 
7.0). However, this is not the physiological pH of the female reproductive tract where the 
microbicide is intended to be used. In this study, we assessed the neutralization capacity 
of VRCO1 in the presence of 1% L-LA at acidic pH using the TZM-BL assay. Firstly, we 
determined the optimal concentration of VRCO1 in solution or in MB66 film and its 
activity over a time-course (Figure 2 and 3 respectively).  Both VRCO1 and MB66 
(100µg/ml and 10µg/ml) were able to inhibit HIV infection completely at 30 minutes and 
4 hours. We then determined the neutralization activity of VRCO1 in the presence of 1% 
L-LA which is present within the lower female reproductive tract, the site of application 
for the microbicide. Neutralization activity of VRCO1 (10µg/ml, 30 minute incubation) 
at neutral pH was slightly lower than that in presence of 1% L-LA (Figure 4a) but 
statistically significant (p=0.008). The difference between inhibition of HIV infection by 
MB66 film (10µg/ml, 30 minute incubation) at neutral and acidic pH was very small but 
statistically significant (p= 0.028). L-LA only was also able to inhibit HIV infection  
(Figure 4d) which is consistent with previous work by Aldunate and colleagues who 
showed that lactic acid can inactivate HIV (Aldunate, Tyssen et al. 2013). 
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Figure 2.  Comparison of antibody neutralization activity in media and lactic acid 
with decreasing concentration of VRCO1 over a time course. Inhibition of HIV 
infection was at 30 minutes, 4 and 24 hours time points.  A) Neutralization activity of 
VRCO1 in media. B) Neutralization activity of VRCO1 in presence of 1% L-LA. Data is 
representative of 3 experiments and is expressed as mean + SEM 
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Figure 3.  Comparison of antibody neutralization activity in media and lactic acid 
with decreasing concentration of VRCO1 over a time course. Inhibition of HIV 
infection was at 30 minutes, 4 and 24 hours time points.  A) Neutralization activity of 
MB66 in media. B) Neutralization activity of MB66 in presence of 1% L-LA. Data is 
representative of 3 experiments and is expressed as mean + SEM 
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Figure 4. Time course of neutralizing activity of antibody in media and acid 
A) Comparison of neutralization activity of VRCO1 and MB66 in media and acid at 30 
minutes. B) Comparison of neutralization activity of VRCO1 and MB66 in media and 
acid at 4 hours. C)  Comparison of neutralization activity of VRCO1 and MB66 in media 
and acid at 24 hours. D) Time course showing inhibition of HIV infection by L-LA. Data 
is representative of 3 experiments and is expressed as mean + SEM. * p<0.05 by Holm-
Sidak method.  
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3.2 RESPONSIVENESS OF VEC TISSUES TO L-LA TREATMENT 
To determine the effects of L-LA treatment on the vaginal epithelium, varying 
concentrations of L-LA were added to the apical surfaces of VEC tissues for 3 hours.  All 
tissues had TEER readings above 300 ohms indicating that tissue integrity was not 
disrupted by treatments. Cytokines in the apical and basal culture supernatants were 
measured after 24 hour incubation. Basal supernatants had significantly higher 
concentrations of cytokines than apical supernatants in both untreated and LA-treated 
cultures. We compared cytokine concentrations in supernatants of media- versus L-LA-
treated tissues. Treatment of VEC tissues with L-LA elicited very low amounts of IL-1β 
and RANTES (Figure 5); basal concentrations were higher than apical concentrations 
(p<0.001) for both cytokines. VEC tissues treated with 0.5% and 4% L-LA had 
significantly higher concentrations of IL-1β in their basal supernatants compared to the 
media control (p<0.05). In addition, we determined secretion of TNF-alpha, IL-8 (Figure 
6a and 6b respectively) and IL-1RA upon treatment of VEC tissues with L-LA. 1% L-LA 
elicited significantly higher TNF alpha in basal supernatant than in media (Figure 6a). 
Apical supernatants of tissues treated with 2% and 4% L-LA had significantly lower IL-8 
than media. IL-1RA expression by VEC tissues was significantly higher than expression 
of all other cytokines (p<0.0001) irrespective of the concentration of L-LA (Figure 7b). 
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Figure 5. IL-1β and RANTES expression in basal and apical supernatants 
of VEC tissues treated with L-LA 
A) IL-1β was higher in basal supernatants than apical supernatants. B) 
RANTES expression by VEC tissues after 3 hour treatment with varying 
concentrations of L-LA. Data shown is mean with SD.  
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Figure 6. TNF alpha and IL-8 expression in basal and apical supernatants of 
VEC tissues treated with L-LA. 
A) Basal concentrations of TNF alpha were significantly higher (p<0.001) in 
tissues treated with 1% L-LA compared to the untreated tissues (media). B) Higher 
concentrations of L-LA elicited significantly lower concentrations of IL-8 
(p<0.001) in their apical supernatants when compared to media control. Data 
represented is mean with SD. *p<0.005 by Dunnett’s multiple comparisons test. 
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Figure 7. Cytokine profile of VEC tissues treated with L-LA. 
A) IL-1RA expression by VEC tissues in dose response to L-LA. B) Cytokine 
expression by VEC tissues in response to 1% L-LA treatment. L-LA treatment 
elicited very high concentrations of IL-1RA. 
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3.3 EFFECT OF L-LA ON RESPONSIVENESS OF VEC TISSUES TO TLR 
AGONISTS 
VEC tissues were treated with Poly I: C or Pam3CSK in the presence and absence of 1% 
L-LA to determine whether L-LA has an anti-inflammatory effect. TLR agonists were 
added to the basal surfaces of VEC tissues for 24 hours and cytokine concentrations in 
the supernatants were determined by ELISA. Experiments were performed in triplicate or 
quadruplicate. Data shown is representative of 3 experiments. IL-1β expression was 
higher in basal versus apical supernatants and Poly I: C elicited a significantly greater IL-
1β response than Pam3CSK (p<0.05) as measured in basal supernatants (Figure 8). L-LA 
(1%) added to apical surfaces of VEC tissues significantly decreased expression of IL-1β 
in basal supernatants of Poly I: C stimulated tissues. L-LA did not have a significant 
effect on Pam3CSK treated tissues. 
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Figure 8. Effect of L-LA on IL-1β expression of VEC tissues treated with 
TLR agonists 
L-LA significantly lowered IL-1β secretion by VEC tissues in response to Poly 
I: C (PIC) treatment (p<0.05). 
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L-LA treatment significantly increased IL-1RA expression in the basal supernatants of 
VEC tissues treated with Pam3CSK (p<0.05) compared to those treated with Pam3CSK 
only. Basal supernatants of tissues treated with only Poly I: C had lower IL-1RA 
concentrations compared to those treated with both 1% L-LA and Poly I: C although the 
difference is not statistically significant (Figure 9). 
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Figure 9. IL-1RA expression in response to treatment with TLR agonists 
L-LA treatment in presence of either Poly I: C (PIC) or Pam3CSK elicited a greater IL-
1RA response than media or the TLR agonists alone. Data reported is means with SD. 
P<0.05 as calculated by Tukey’s multiple comparisons test. 
 
Treatment of VEC tissues with Poly I: C elicited the greatest IL-6 expression when 
compared to Pam3CSK and TNF-alpha, the positive control in basal supernatants. L-LA 
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lowered expression of IL-6 in basal supernatants of VEC tissues treated with Poly I: C 
and TNF-alpha although the decrease was not statistically significant (Figure 10). 
Concentrations of IL-6 in apical supernatants were significantly lower than that in basal 
supernatants. 
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Figure 10. IL-6 expression by VEC  in response to TLR agonists 
L-LA lowered IL-6 responses of VEC tissues treated with Poly I: C and TNF-alpha  
 
Treatment of VEC tissues with Poly I: C and Pam3CSK in the presence of 1% L-LA 
elicited a lower expression of TNF-alpha in basal supernatants as compared to tissues 
treated with the TLR agonists only, although the decrease was not statistically significant 
(Figure 11). 
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Figure 11. Expression of TNF-alpha in apical and basal supernatants of VEC tissues 
treated with TLR agonists 
L-LA lowered TNF-alpha concentrations secreted by VEC tissues in response to TLR 
agonists in the basal supernatants 
 
3.4 HISTOLOGY OF L-LA TREATED VEC TISSUES 
The morphology of VEC tissues treated with L-LA was assessed by hematoxylin and 
eosin staining. The epithelia of treated tissues appeared normal when compared to 
untreated tissues. This is in agreement with cytokine results that showed low expression 
of pro-inflammatory markers IL-1β and TNF-alpha. 
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Figure 12. H and E staining of L-LA treated VEC tissues 
A) Untreated VEC tissue B) VEC tissue treated with 0.5% L-LA C) VEC tissue treated 
with 1% L-LA D) VEC tissue treated with 2% L-LA. Epithelia appeared normal. 
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CHAPTER FOUR 
DISCUSSION 
In this study, the neutralization activity of VRCO1, a monoclonal anti-HIV-1 antibody 
was evaluated under acidic conditions normally found in the vagina. Previous work had 
assessed activity of these antibodies at neutral pH yet when formulated into microbicides 
they are intended for use in the lower female reproductive tract whose pH is acidic due to 
the lactic acid produced by the resident commensal bacteria (Euler, Bunnik et al. 2011; 
O'Hanlon, Moench et al. 2013). We determined the ability of VRCO1 in solution and 
extracted from a microbicide film to inhibit HIV infection in the presence of 1% L-LA at 
pH of 3.9 (vaginal conditions). The acidic environment did not affect the antibodies’ 
ability to prevent HIV infection. During production, antibodies are usually exposed to 
acidic environments during their purification and this raises the question of stability and 
possible conformational changes.  Acid exposure (pH 2.7-3.9) induces limited 
conformational changes on antibodies implying that functionality of antibodies is 
unhindered in acidic environments (Ejima, Tsumoto et al. 2007).  Physiologically, 
antibodies can be found within the lower female reproductive tract, a characteristically 
acidic environment where they function to curb invading pathogens (Wira, Fahey et al. 
2005) . Therefore VRCO1 activity at low pH is consistent with what is believed to occur 
in-vivo. We also demonstrated that L-LA can inhibit HIV infection and this is consistent 
with previous reports by Aldunate and colleagues (Aldunate, Tyssen et al. 2013) which 
showed that concentrations of L-LA within the vaginal environment can potently 
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inactivate HIV and this virucidal activity was due to the protonated lactic acid rather than 
acidity. 
STIs are a major health concern affecting millions of people globally and it is imperative 
to continue the search for preventive strategies. In this study we hypothesized that L-LA 
has anti-inflammatory properties and assessed its potential as microbicide. Firstly, we 
determined the immune response of vaginal epithelium elicited by L-LA using the VEC 
tissue models. Basal supernatants had the greatest amount of cytokines compared to 
apical supernatants after treatment of VEC tissues with L-LA. The low response of the 
apical surfaces further supports the known tolerance of the vaginal epithelium towards 
commensal bacteria and their metabolites (Rose, McGowin et al. 2012). Low 
concentrations of IL-1β and RANTES were expressed by VEC tissues in response to L-
LA treatment. VEC tissues expressed significantly high concentrations of IL-1RA 
(p<0.0001), an anti-inflammatory cytokine, but expression of Il-1RA in unstimulated 
tissues was not affected by  L-LA regardless of incubation time and L-LA doses. 
Stimulation of VEC tissues with the TLR3 agonist Poly I: C induced upregulated 
expression of IL-1β, TNF-alpha and IL-6, which was dampened by L-LA. This is in 
contrast to work by Mossop and colleagues that showed that L-LA (15mM) in 
combination with Poly I: C enhanced expression of IL-1β and IL-8 by vaginal epithelial 
cells in a standard tissue culture set up (Mossop, Linhares et al. 2011). This difference 
could be due to the difference in L-LA concentrations used in the two experiments. Our 
experiments were set at physiologic pH and concentrations of L-LA found in healthy 
 33 
 
asymptomatic women.  L-LA elicited significantly higher IL-1RA concentrations when 
apically added to the TLR agonist-treated VEC tissues. These data suggest that L-LA 
elicits an anti-inflammatory response in the vaginal epithelium and confirms previous 
reports of anti-inflammatory effects of LA on vaginal epithelium (G Tachedjian 2015). 
Previous reports have indicated the benefits of having lactic acid producing bacteria in 
the female reproductive tract and in the gut (McLoughlin and Mills 2011; Aldunate, 
Srbinovski et al. 2015). By maintaining an anti-inflammatory environment within the 
female reproductive tract, lactic acid may lower transmission of sexually transmitted 
diseases such as HIV and gonorrhea whose spread and pathology is associated with 
inflammation. 
This report highlights the potential use of L-LA as a microbicide due to its virucidal 
activity and anti-inflammatory properties. In addition, the functionality of VRCO1 in an 
acidic milieu was assessed and its activity will not be diminished at its intended site of 
application. Overall, we looked at the responses of the vaginal epithelium to L-LA in the 
presence or absence of TLR agonists. There is still a need to elucidate the exact 
mechanisms by which L-LA confers immuno-modulatory properties within the female 
reproductive tract. 
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